Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-248-4 | CAS number: 80-08-0
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 3 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The whole database is excellent, because dapsone has a dual use as an industrial chemical and a pharmaceutical.
Additional information
In the 90d gavage study in the rat treatment-related findings were observed at 30 mg/kg/day or above. The main effects were cyanosis of the skin, hyperactivity, increased WBC count, decreased RBC count, hemoglobin concentration and hematocrit., increased prothrombin time, spleenomegaly (especially in males), mild spleenic congestion, and mild pigmentation of the spleen. These effects are typical for methemoglobinaemia. Human experience (due to the dual use of dapsone as a pharmaceutical) shows the same effect at doses above the usual therapeutic dose of 100 mg/person/day.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The selected study is a 90d study with most parameters evaluated. No data are on neurotoxicity (this endpoint is covered by human experience due to dapsone use in leprosy treatment for 60 years)
Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: spleen; cardiovascular / hematological: other; digestive: liver
Justification for classification or non-classification
According to Guidance to Regulation (EC) No 1272/2008 on classification, labelling and packaging
(CLP) of substances and mixtures, the substance should be classified for Specific Target Organ Toxicity after repeated exposure Category 2 with effects on blood (methemoglobinaemia), Spleen and liver.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
